Over the past few weeks new discoveries and resources on COVID-19 research are emerging rapidly as virologists, epidemiologists, public health officials, clinicians, editors, and other scientists and public sectors work tirelessly to understand and combat the pandemic. Efforts by scientists and journals alike to share information as quickly as possible have spawned numerous open-access resources, which have greatly accelerated the pace of discovery and application of protective public health measures. These resources form the foundation for collaborative and world-wide efforts to search for drugs, vaccines and other medical interventions as we race against the spread of disease.
Social media has provided a platform for the rapid dissemination of these resources and discoveries, between and across research groups. We have been following the story and sharing these advances with the Keystone Symposia community as they emerge. With so much going on right now, it can be hard to keep up, so here we compile some of the most impactful posts from the last few weeks into one easy-to-access reference list. Bookmark and share!
See the latest COVID-19 discoveries and breakthroughs on our Twitter feed:
Special Symposium on COVID-19 Webcasts:From The Conference on Retroviruses and Opportunistic Infections (CROI), held virtually March 8-11, 2020, this special session highlights the latest epidemiology, public health and virology information on COVID-19 from global experts:
Zunyou Wu-Chief Epidemiologist at Chinese Center for Disease Control & Prevention
Anthony S Fauci--National Institute of Allergy and Infectious Diseases, USA
John T Brooks- Centers for Disease Control & Prevention, USA
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.